Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06096064 · ClinicalTrials.gov registry record
Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients
A clinical trial, sponsored by Methodist Health System.
- Completed
- Registry status
- 100
- Enrollment target
NCT06096064 is a clinical trial that has completed, run by Methodist Health System. The registered enrollment target is 100 participants.
The verdict
NCT06096064 has completed, sponsored by Methodist Health System.
- COMPLETED
- Registry status
- 100 participants
- Enrollment target
Study Summary
Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus followed by a continuous infusion that is adjusted based on the patient's subsequent partial thromboplastin time (PTT) levels
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2023-08-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06096064
The ClinicalTrials.gov registry entry for NCT06096064 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Methodist Health System, which has 125 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06096064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06096064 about?
NCT06096064 is a clinical study titled "Medication Use Evaluation (MUE) for Continuous Heparin Infusions in Hospitalized Patients". Unfractionated heparin (UFH) is an anticoagulant to prevent thrombus formation or worsening of an existing thrombus. It is indicated for patients with deep vein thrombosis/pulmonary embolism (DVT/PE) or acute coronary syndrome (ACS). Unfractionated heparin treatment consists of an initial bolus foll...
What is the current status of trial NCT06096064?
This trial is currently completed. The enrollment target is 100 participants. The study started on 2022-10-31. Estimated completion is 2023-08-21.
Who is sponsoring clinical trial NCT06096064?
This trial is sponsored by Methodist Health System, which has 125 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.